TechNewsHeaven {{}}

Under “right-to-try” law, therapy may go for $300K—with no proof it will work
2018-06-22T15:45:47+00:00 - Beth Mole / Ars Technica
But despite the potentially hefty price tag that patients would likely pay out of pocket, there’s no proof that the therapy stops the progression of the disease or improves symptoms. But under the new “right-to-try” law, the biotech company doesn’t need such proof to sell its therapy. The law was pitched as a compassionate measure to allow patients with life-threatening illnesses easier access to experimental drugs. The office of Senator Johnson didn’t respond to questions specifically about Brainstorm’s plans but pointed out that the right-to-try law limits companies to charging “direct costs only” for experimental therapies. Brainstorm began considering selling NurOwn after eager patients started requesting access to the therapy under the new law, Lebovits said.

Your favorite news

Popular news

Recommended news